Search
forResearch 10 of 28
- 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- Protective mitophagy in human hypoxic cardiomyocytes: mechanistic insights into SGLT2 inhibitor Dapagliflozin cardioprotection in ischemic injury
- Olorofim Effectively Eradicates Dermatophytes <i>In Vitro</i> and <i>In Vivo</i>
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →